News Releases Keyword Search Year None201920182017 Date Title Nov 07, 2019 Aileron Therapeutics Reports Third Quarter 2019 Results Oct 31, 2019 Aileron Therapeutics to Report Third Quarter 2019 Financial Results on November 7th Oct 29, 2019 Aileron Therapeutics Announces Positive Nonclinical Myelopreservation Results for ALRN-6924 at the 2019 AACR-NCI-EORTC Conference Oct 21, 2019 Aileron to Present Nonclinical Myelopreservation Data for ALRN-6924 at the 2019 AACR-NCI-EORTC Conference on October 29th Oct 16, 2019 Aileron Therapeutics Announces the Initiation of Patient Treatment in its First Clinical Ph1b/2 Trial of ALRN-6924 as a Myelopreservation Agent Sep 28, 2019 Aileron Presents Positive Interim Phase 2a Data for ALRN-6924 in Combination with Pfizer’s Palbociclib at the 2019 Congress of the European Society for Medical Oncology Sep 24, 2019 Aileron to Present Interim Phase 2a Clinical Data for ALRN-6924 in Combination with Pfizer’s IBRANCE® (palbociclib) in Patients with MDM2-Amplified Cancers at the 2019 Congress of the European Society for Medical Oncology Sep 09, 2019 Aileron Therapeutics Announces Management Change Sep 03, 2019 Aileron Therapeutics to Present at the H.C. Wainwright 21st Annual Global Investment Conference in New York Aug 06, 2019 Aileron Therapeutics Reports Second Quarter 2019 Financial Results Pagination Current page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Next page next › Last page last »
Oct 29, 2019 Aileron Therapeutics Announces Positive Nonclinical Myelopreservation Results for ALRN-6924 at the 2019 AACR-NCI-EORTC Conference
Oct 21, 2019 Aileron to Present Nonclinical Myelopreservation Data for ALRN-6924 at the 2019 AACR-NCI-EORTC Conference on October 29th
Oct 16, 2019 Aileron Therapeutics Announces the Initiation of Patient Treatment in its First Clinical Ph1b/2 Trial of ALRN-6924 as a Myelopreservation Agent
Sep 28, 2019 Aileron Presents Positive Interim Phase 2a Data for ALRN-6924 in Combination with Pfizer’s Palbociclib at the 2019 Congress of the European Society for Medical Oncology
Sep 24, 2019 Aileron to Present Interim Phase 2a Clinical Data for ALRN-6924 in Combination with Pfizer’s IBRANCE® (palbociclib) in Patients with MDM2-Amplified Cancers at the 2019 Congress of the European Society for Medical Oncology
Sep 03, 2019 Aileron Therapeutics to Present at the H.C. Wainwright 21st Annual Global Investment Conference in New York
